Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Biener, L; Mümmler, C; Hinze, CA; Suhling, H; Korn, S; Fisser, C; Biener, A; Pizarro, C; Lenoir, A; Hackl, C; Skowasch, D; Milger, K.
Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany.
J Allergy Clin Immunol Pract. 2024; 12(9):2399-2407.e5 Doi: 10.1016/j.jaip.2024.05.052
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Milger-Kneidinger Katrin

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND: Tezepelumab is a novel biologic blocking thymic stromal lymphopoetin, approved for severe asthma irrespective of biomarker levels or phenotype. OBJECTIVE: To characterize a real-world tezepelumab patient cohort and the efficacy among various asthma phenotypes. METHODS: We performed a retrospective, multicenter study on patients with severe asthma initiating tezepelumab. Clinical response was evaluated at 3 and 6 months. RESULTS: We included 129 patients with an average age of 52.5 ± 13.1 years, 59.7% were female. The majority (86.0%) had increased type 2 (T2) biomarkers, 68.2% an allergic and 31.8% an eosinophilic phenotype. 23.3% of patients were biologic-naive. 22 (18.2%) patients discontinued tezepelumab therapy owing to suspected side effects or insufficient efficacy. At 6 months' follow-up, median reduction in annualized exacerbation rate was-1 [25th percentile; 75% percentile {-2.9; 0.0}], the reduction of oral corticosteroid dose among patients with long-term oral corticosteroid therapy was -5 mg [-10; 0] and the Asthma Control Test (ACT) improved by 2 [0; 5] points. A treatment response according to Biologic Asthma Response Score of 80.8% was demonstrated. There were no significant differences in treatment response between T2-high versus T2-low, early- versus adult-onset and eosinophilic versus non-eosinophilic asthma. Prior treatment with other biologics was associated with inferior treatment response. CONCLUSIONS: In this real-life cohort, including a large proportion of patients with history of previous biologic use and encompassing various subgroups, the majority responded to tezepelumab. Our data further suggest a steroid-sparing effect of tezepelumab.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Asthma - drug therapy

Female - administration & dosage

Male - administration & dosage

Middle Aged - administration & dosage

Adult - administration & dosage

Antibodies, Monoclonal, Humanized - therapeutic use

Anti-Asthmatic Agents - therapeutic use

Retrospective Studies - administration & dosage

Germany - administration & dosage

Aged - administration & dosage

Treatment Outcome - administration & dosage

Severity of Illness Index - administration & dosage

Adrenal Cortex Hormones - therapeutic use

Find related publications in this database (Keywords)

Severe asthma

Biologic

Antibody

Tezepelumab

Real-world

Switching

© Med Uni Graz • Imprint